Changes

==Gene Overview==

==Gene Overview==

The function of the normal BCR gene product is as a GTPase-activating protein for RAC1 and CDC42.  Promotes the exchange of RAC or CDC42-bound GDP by GTP, thereby activating them.  The protein has serine/threonine kinase activity.  (1)

The function of the normal BCR gene product is as a GTPase-activating protein for RAC1 and CDC42.  Promotes the exchange of RAC or CDC42-bound GDP by GTP, thereby activating them.  The protein has serine/threonine kinase activity.  (9)

By far the most prevalent BCR alteration associated with cancer are the fusions of the BCR gene with a number of parters, but especially with the ABL1 gene. A reciprocal translocation between chromosome 22 (BCR locus) and chromosome 9 (ABL1 locus) produces the Philadelphia chromosome t(9;22)(q34.1;q11.2), which is prevalent in Chronic Myeloid Leukemia (1, 2) and to a lesser extent in B-cell Acute Lymphoblastic Leukemia and T-cell Acute Lymphoblastic Leukemia. The head to tail arrangement of the BCR-ABL1 fusion gene results in an activated tyrosine kinase activity (6).

By far the most prevalent BCR alteration associated with cancer are the fusions of the BCR gene with a number of parters, but especially with the ABL1 gene. A reciprocal translocation between chromosome 22 (BCR locus) and chromosome 9 (ABL1 locus) produces the Philadelphia chromosome t(9;22)(q34.1;q11.2), which is prevalent in Chronic Myeloid Leukemia (1, 2) and to a lesser extent in B-cell Acute Lymphoblastic Leukemia and T-cell Acute Lymphoblastic Leukemia. The head to tail arrangement of the BCR-ABL1 fusion gene results in an activated tyrosine kinase activity (6).

Mention that is haas coiled coil domain and prob. aggregates as Fusion BRC-ABL1.

It appears that the N-terminal domain of BCR can cause oligomerization of the BCR-ABL1 protein product, thus activating the ABL1 tyrosine kinase domain of the fusion protein (10, 11, 12).

==Common Alteration Types==

==Common Alteration Types==